Tagged with Novo Nordisk

Greece After 15 years of economic struggles coupled with political swings to the left and right, Greece seems to be on its surest footing in decades. Indeed, the Economist observed that the May 2023 election victory of incumbent Greek Prime Minister Kyriakos Mitsotakis (and the heavy defeat handed to his left…

LatAm A vibrant and diverse continent, home to over 650 million people and the highest life expectancy among developing regions, Latin America is now emerging as a globally relevant life sciences investment destination. LatAm has a robust heritage of scientific achievement – Bernardo Houssay (1947) and César Milstein (1984) of Argentina…

USA After considerable government pressure to reduce insulin costs in the US, Eli Lilly recently slashed its prices by as much as 70 percent, followed by competitors Novo Nordisk and Sanofi. While these steps to make insulin more affordable, together with the US Medicare insulin price cap that came into effect…

LatAm Latin America is renowned for its creative geniuses – think footballers like Lionel Messi and Pelé; magical realist authors such as Gabriel García Márquez and Isabel Allende; and ground-breaking artists like Frida Kahlo and Wilfredo Lam. This tradition of creativity permeates the continent’s population, who are well used to dreaming…

Greece The European Union’s decision to mitigate the effects of the COVID-19 pandemic by launching its Recovery and Resilience Facility (RRF) and moving away from its past austerity policies is particularly significant for Greece. Severely hit by the financial crisis a decade ago and thrown off its course to recovery by…

Global Over the past year, PharmaBoardroom has spoken to pharma executives the world over, collecting unique perspectives from all sides of the industry. Here are the ten most-read interviews of 2022 that range from conversations with one of Korea’s top CDMOs to the American generics association and the Italian regulatory agency,…

Greece Novo Nordisk veteran and president of Greece’s leading industry organisation, the Hellenic Association of Pharmaceutical Companies (SFEE), Olympios Papadimitriou speaks to PharmaBoardroom about the impact of the country’s economic comeback on the pharma industry, the challenges of Greece’s clawback system, the Recovery and Resilience funds that will be dedicated in…

Americas While regulatory agencies in several Latin American countries have made significant efforts to improve processes and accelerate approval times, a number of access hurdles still remain across the region. Here, the representatives of some of pharma’s most important companies in LatAm share their experiences of the evolution of market access…

Americas Two Big Pharma SVPs with responsibility for the entirety of Latin America weigh in on the management challenges inherent in LatAm and what they look for when appointing country managers in their region.   LatAm’s regional pharma market of USD 98 billion looks set to be the fastest growing in…

LatAm Novo Nordisk’s Latin America lead Allan Finkel outlines the “alarming” burden of diabetes and obesity in his region, the progress that has been made via national campaigns against diabetes, and why countries in LatAm need to recognise obesity as the disease it is considering its heavy impact on patients’ lives…

China Writing in the May edition of DIA’s Global Forum magazine, Xu Wang of Novo Nordisk China looks at the new drug approvals in China in 2021. Among other highlights, the approval of two CAR-T products signal that CAR-T treatment has finally entered the commercialization stage. The number of new drug…

United Kingdom Just one year after the UK government published its Life Science Vision, outlining the ambitions of the government and the life science sector for the next 10 years, the Association of the British Pharmaceutical Industry (ABPI) has appointed a new president who will take on the plan.  The Association of…